Randomized open-label trial demonstrates safety and moderate metabolic improvements in established type 1 diabetes, indicating potential therapeutic benefit.
Transplantation of UC-MSC and aBM-MNC was safe and associated with moderate improvement of metabolic measures in patients with established T1D.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: